ArticleCureus2026
Recurrent Metastatic Malignant Wolffian Tumour: A Rare and Aggressive Clinical Course.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wolffian tumours (female adnexal tumours of probable Wolffian origin, FATWO) are rare mesonephric duct-derived neoplasms with variable malignant potential and challenging diagnosis. A 68-year-old woman underwent complete resection for a left tubo-ovarian mass and was diagnosed with a localised Wolffian tumour with malignant potential. After 22 months of surveillance, she re-presented with malignant ascites and extensive peritoneal dissemination showing anaplastic transformation and underwent cytoreductive surgery. Adjuvant chemotherapy was poorly tolerated and ineffective, with rapid progression despite treatment, leading to best supportive care. This case highlights the diagnostic complexity and potential aggressive behaviour of malignant Wolffian tumours, the limited efficacy and tolerability of chemotherapy in advanced disease, and the need for early integration of palliative care when disease becomes refractory.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.